Please assess the completion status of the following clinical trial:

Trial Title: GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* EGFR- tyrosine kinase inhibitor (TKI) naive patients with histologically confirmed locally advanced or metastatic NSCLC with activating EGFR-mutations~* Age \>= 18 years~* No diagnostic or therapeutic measures beyond routine clinical practice are required~* Patients for whom the treating physician has decided to initiate treatment with GIOTRIF~* Written informed consent prior inclusion~Exclusion criteria:~* Contraindication for Afatinib according to the Summary of Product characteristics~* Participation in another clinical study until 30 days after end of treatment~* Prior systemic chemotherapy (Neo-/adjuvant therapy is permitted)~* Previous treatment with an EGFR-tyrosine kinase inhibitor~* Patients not willing or not able to fill in quality of life questionnaires~* Patients with missing or impaired legal capacity~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Afatinib (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).